Related Experiment Video
Updated: Mar 5, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer
Xiaoju Wang1, Yuanyuan Qiao2, Irfan A Asangani2
1Michigan Center for Translational Pathology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan, 1400 East Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA.
Abstract:
Transcription factors play a key role in the development of diverse cancers, and therapeutically targeting them has remained a challenge. In prostate cancer, the gene encoding the transcription factor ERG is recurrently rearranged and plays a critical role in prostate oncogenesis. Here, we identified a series of peptides that interact specifically with the DNA binding domain of ERG. ERG inhibitory peptides (EIPs) and derived peptidomimetics bound ERG with high affinity and specificity, leading to proteolytic degradation of the ERG protein. The EIPs attenuated ERG-mediated transcription, chromatin recruitment, protein-protein interactions, cell invasion and proliferation, and tumor growth. Thus, peptidomimetic targeting of transcription factor fusion products may provide a promising therapeutic strategy for prostate cancer as well as other malignancies.
Insights
Researchers developed novel peptides that target the ERG transcription factor in prostate cancer. These ERG inhibitory peptides (EIPs) and peptidomimetics degrade the ERG protein, inhibiting cancer growth and offering a potential new therapy.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Transcription factors are crucial in cancer development, but challenging to target therapeutically.
- The ERG gene fusion is a key driver in prostate cancer oncogenesis.
Purpose of the Study:
- To identify novel therapeutic agents targeting the ERG transcription factor in prostate cancer.
- To evaluate the efficacy of ERG inhibitory peptides (EIPs) and peptidomimetics.
Main Methods:
- Identification of peptides binding to the ERG DNA binding domain.
- Assessment of EIPs and peptidomimetics for ERG binding affinity and specificity.
- Evaluation of EIPs' effects on ERG protein levels, transcriptional activity, and downstream signaling.
- In vitro and in vivo studies on cancer cell invasion, proliferation, and tumor growth.
Main Results:
- Peptides specifically interacting with the ERG DNA binding domain were identified.
- ERG inhibitory peptides (EIPs) and derived peptidomimetics demonstrated high affinity and specificity for ERG.
- These agents induced proteolytic degradation of the ERG protein.
- EIPs effectively attenuated ERG-mediated transcription, chromatin recruitment, protein-protein interactions, cell invasion, proliferation, and tumor growth.
Conclusions:
- Peptidomimetic targeting of ERG represents a promising therapeutic strategy for prostate cancer.
- This approach may also be applicable to other malignancies driven by transcription factor fusion products.
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...